Comparative study of [¹⁸F]AlF-NOTA-FAPI-RGD and [¹⁸F]FDG/[¹⁸F]AlF-NOTA-FAPI-04 PET/CT in renal cell carcinoma.

ABSTRACT: Renal cell carcinoma (RCC) is a significant global health concern, and the early diagnosis and accurate staging of clear cell renal cell carcinoma (ccRCC) remain major challenges. [¹⁸F]FDG PET/CT is not ideal for diagnosing ccRCC due to the low glucose metabolism potential of cancer cells. Both fibroblast activation protein (FAP) and the angiogenic integrin α_vβ₃ receptor are closely linked to the pathogenesis and progression of ccRCC. The aim of this study is to evaluate a novel radiopharmaceutical [¹⁸F]AlF-NOTA-FAPI-RGD (denoted as [¹⁸F]AlF-LNC1007), a dual-targeting heterodimer tracer targeting both FAP and integrin α_vβ₃, and to compare the diagnostic value of [¹⁸F]AlF-LNC1007 with [¹⁸F]FDG

SUBMITTER: Gao H 

PROVIDER: S-EPMC12068302 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature